Claims for Patent: 8,927,530

Summary for Patent: 8,927,530

Title:	Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
Abstract:	The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. ##STR00001##
Inventor(s):	Valsasina; Barbara (Milan, IT), Beria; Italo (Nerviano, IT), Ciavolella; Antonella (Bizzarone, IT), Ballinari; Dario (San Donato Milanese, IT), Pesenti; Enrico (Parabiago, IT), Croci; Valter Domenico (Nerviano, IT), Moll; Juergen (Appiano Gentile, IT)
Assignee:	Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)
Application Number:	13/321,024
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,927,530
Patent Claims:	1. A combination comprising a synergistic amount of (a) a compound of formula (I) ##STR00003## and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, an alkylating or an alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein the active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, wherein the topoisomerase I inhibitor is selected from the group consisting of topotecan, SN-38, CPT11 and 9-nitrocamptothecin. 2. The combination according to claim 1 wherein the antimetabolite agent is selected from the group consisting of 5-fluorouracil, azacytidine, capecitabine, cytarabine, gemcitabine, pemetrexed, methotrexate, edatrexate, hydroxyurea, fludarabine and mercaptopurine. 3. The combination according to claim 2 wherein the antimetabolite agent is gemcitabine or cytarabine. 4. The combination according to claim 1 wherein the alkylating or alkylating-like agent is selected from the group consisting of nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil), aziridines (thiotepa), nitrosoureas (carmustine, lomustine, semustine), triazenes (dacarbazine and temozolomide) and platinum derivatives (cisplatin, oxaliplatin, carboplatin and satraplatin). 5. The combination according to claim 4 wherein the alkylating or alkylating-like agent is cisplatin. 6. The combination according to claim 1 wherein the intercalating agent is bleomycin. 7. The combination according to claim 1 wherein the topoisomerase I inhibitor is SN-38 or CPT11. 8. The combination according to claim 1 wherein the topoisomerase II inhibitor is selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, etoposide and teniposide. 9. The combination according to claim 8 wherein the topoisomerase II inhibitor is doxorubicin. 10. The combination according to claim 1 wherein the antimitotic agent is selected from the group consisting of paclitaxel, docetaxel, ixabepilone, vinblastine, vincristine, vindesine and vinorelbine. 11. The combination according to claim 10 wherein the antimitotic agent is paclitaxel. 12. The combination according to claim 1 wherein the kinase inhibitor is selected from the group consisting of sorafenib, dasatinib, gefitinib, erlotinib, sunitinib, imatinib, nilotinib and lapatinib. 13. The combination according to claim 12 wherein the kinase inhibitor is sorafenib or dasatinib. 14. The combination according to claim 1 wherein the proteasome inhibitor is bortezomib. 15. The combination according to claim 1 wherein an antibody inhibiting a growth factor or its receptor is selected from the group consisting of of bevacizumab (antibody to vascular endothelial growth factor), cetuximab, panitumumab, matuzumab, nimotuzumab (antibodies to epidermal growth factor receptor), trastuzumab and pertuzumab (antibodies to ErbB2). 16. The combination according to claim 15 wherein the antibody inhibiting a growth factor or its receptor is bevacizumab. 17. A pharmaceutical composition comprising the combination according to claim 1 in association with a pharmaceutically acceptable carrier, diluent or excipient. 18. The combination according to claim 1 or a pharmaceutical composition comprising the combination according to claim 1 in association with a pharmaceutically acceptable carrier, diluent or excipient, for simultaneous, separate or sequential use. 19. A commercial kit comprising, in a suitable container means, a combination as defined in claim 1 or a pharmaceutical composition comprising the combination according to claim 1 in association with a pharmaceutically acceptable carrier, diluent or excipient, for simultaneous, separate or sequential use thereof.

Details for Patent 8,927,530

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-05-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-05-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2029-05-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2029-05-26